Sun Pharma Advanced Research Company Ltd up by 19.24 percent | Espresso

EspressoLogy

Espresso shot of the day – Sun Pharma Advanced Research Company Ltd up by 19.24 percent

May 10, 2021
Espresso shot of the day – Sun Pharma Advanced Research Company Ltd up by 19.24 percent

SUN PHARMA ADVANCED RESEARCH COMPANY LTD 220.35 (+19.24%) BSE – INE232I01014 | 10TH MAY 2021

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. They strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic collaborating with academic innovators and bio-pharma entrepreneurs fuel their engine with potentially high impact ideas. They collaborate with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes their future. Their aim is to consistently lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. They realised their dream when their helped patients led more fulfilling lives. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency. Their accountability to patients seek to serve, and investors who enable them and their commitment to sustainable human progress are key components of their identity – A responsible innovator inspired by life’s amazing ability to learn, evolve and survive. They exist because they seek to be part of the solution.

Recent Drivers

  • According to experts, due to the Covid-19 in India and other countries, pharma sector is going to receive major traction in the market leading to higher performance reflecting in their balance sheet. 
  • On 9th May 2021, in a regulatory filing, the company said that The Board of Sun Pharma Advanced Research Company Ltd. will meet on 12 May 2021 to consider and evaluate proposals for raising of funds in one or more tranches by way of issue of Equity Shares or Securities/ Warrants convertible into Equity shares of the Company, through permissible modes including by way of Preferential Issue, subject to the receipt of necessary approvals.
  • The Company also informed that its board will meet on Monday, 17 May 2021, to consider and approve the audited financial results for the quarter and financial year ended 31 March 2021.
  • Sun Pharma Advanced Research Company Ltd. reported net sales at Rs 21.81 crores in December 2020 up 11.28% from Rs 19.60 crores in December 2019.


(Sources: Moneycontrol, Business Standard )

Technical Force*

  • S&P BSE 500 month till date gain up by 2.46%
  • Traded on new 52 week High value – 221.75
  • Touched Upper circuit Rs.221.75
  • Spurt in Volume by more than 9.64 times compare to previous vol. 3 months avg volume – 98,771
  • Quantity traded – 11,32,663 Deliverable quantity – 3,32,039 (29.31%)
  • Stock price has jumped more than 75% from one year low level –  122.75, 18 May 2020
  • Daily RSI (14) is in overbought territory today
  • 52 week high – 221.75 | 52 week low­­ – 122.75

Key Pivot  (Yearly)

R4

R3

R2

R1

PP /FIB PP

S1

S2

S3

S4

Pivot Point

-

372.43

291.57

242.73

161.87

113.03

32.17

-

-

Fibonacci Pivot

291.57

242.02

211.41

191.70

161.87

132.04

112.32

81.71

32.17


Today’s Close

220.35

SMA

BSE

10 DAY

181.63

20 DAY

173.84

50 DAY

165.92

200 DAY

175.85

Some Key Ratios (Source: BSE)

Market Cap: 5774.22 crores

PE: -29.77

OPM%: -297.39

ROE%: 414.98

Promoters holding : 68.46

Prev. Close: 184.80

*Chart And Technical Force data taken from the Binge desktop app.

The scope and usability of this information/data is time-sensitive and market-based, and as such the same may become outdated for the investment decisions of clients, for which Sharekhan comtrade bears no responsibility. References to securities do not constitute a recommendation to buy, sell or hold such securities. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult his own advisors to determine the merits and risks of such an investment. Sharekhan Comtrade Private Limited is under no obligation to update the information in this document from time-to-time.


Chandresh Khona
by Chandresh Khona

Product Offerings Head

A teacher, writer, travel buff and now Espresso's Product Offerings Head. Ten years here has allowed me to lead the digital team at Sharekhan. My true passion lies in stock market charts.